Document is current
Any future updates will be listed below
-
Authors
Pedron, Cibele Nicolaski https://orcid.org/0000-0002-4188-3589
Torres, Marcelo Der Torossian https://orcid.org/0000-0002-6165-9138
Oliveira, Cyntia Silva https://orcid.org/0000-0003-2049-7627
Silva, Adriana Farias
Andrade, Gislaine Patricia
Wang, Yiming https://orcid.org/0000-0003-3657-6100
Pinhal, Maria Aparecida Silva
Cerchiaro, Giselle
da Silva Junior, Pedro Ismael
da Silva, Fernanda Dias https://orcid.org/0000-0002-3508-6241
Radhakrishnan, Ravi
de la Fuente-Nunez, Cesar https://orcid.org/0000-0002-2005-5629
Oliveira Junior, Vani Xavier https://orcid.org/0000-0002-9420-0956
- License Information
-
More Information
Article History
Received: 18 May 2022
Accepted: 17 August 2023
First Online: 19 October 2023
Competing interests
: C.F.N. provides consulting services to Invaio Sciences and is a member of the Scientific Advisory Boards of Nowture S.L. and Phare Bio. The de la Fuente Lab has received research funding or in-kind donations from United Therapeutics, Strata Manufacturing PJSC, and Procter & Gamble for research unrelated to that presented here. A provisional patent application has been filed on the de la Fuente Lab’s related work (ID number 23-10378). All other authors declare no competing interests.
: The study was carried out in compliance with the protocol CEUA/IB #I-1345/15 (blood collection) approved by the Instituto Butantan and the protocol 806763 (skin abscess infection mouse model) approved by the IACUC at the University of Pennsylvania. Data that support the findings of this study are available from the corresponding author upon reasonable request.
